For all investigated cancer types, the author observed that mutations in upstream components of the MAPK/ERK signaling pathway, namely EGFR and RAS family proteins, co-occur much less frequently than expected with oncogenic mutations in BRAF. This evidence concerns the gene EGFR and cancer.